2o8t: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='2o8t' size='340' side='right'caption='[[2o8t]], [[Resolution|resolution]] 1.45Å' scene=''> | <StructureSection load='2o8t' size='340' side='right'caption='[[2o8t]], [[Resolution|resolution]] 1.45Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[2o8t]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[2o8t]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2O8T OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2O8T FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.45Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1PE:PENTAETHYLENE+GLYCOL'>1PE</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2o8t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2o8t OCA], [https://pdbe.org/2o8t PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2o8t RCSB], [https://www.ebi.ac.uk/pdbsum/2o8t PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2o8t ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2o8t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2o8t OCA], [https://pdbe.org/2o8t PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2o8t RCSB], [https://www.ebi.ac.uk/pdbsum/2o8t PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2o8t ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | |||
[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[https://omim.org/entry/601709 601709]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. | |||
== Evolutionary Conservation == | == Evolutionary Conservation == | ||
[[Image:Consurf_key_small.gif|200px|right]] | [[Image:Consurf_key_small.gif|200px|right]] | ||
| Line 22: | Line 25: | ||
==See Also== | ==See Also== | ||
*[[Urokinase 3D Structures|Urokinase 3D Structures]] | *[[Urokinase 3D Structures|Urokinase 3D Structures]] | ||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Huang M]] | |||
[[Category: Huang | [[Category: Huang Z]] | ||
[[Category: Huang | [[Category: Jiang L]] | ||
[[Category: Jiang | [[Category: Yuan C]] | ||
[[Category: Yuan | [[Category: Zhao G]] | ||
[[Category: Zhao | |||
Revision as of 00:15, 28 December 2023
Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q) in complex with Inhibitors
| ||||||||||||
